Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
eli lilly
8
×
life sciences
national blog main
san francisco blog main
8
×
national top stories
san francisco top stories
cancer
fda
indiana blog main
indiana top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
europe blog main
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
deals
europe top stories
novartis
pfizer
startups
abbvie
alzheimer's disease
amgen
What
bio
roundup
drug
cancer
fda
medicines
approval
biotech
black
blueprint
buy
companies
days
debut
diamond
drugs
leading
life
moves
new
regulatory
ret
science
therapeutics
week
acquisitions
address
alliance
approves
august
bails
biggest
brand
bridgebio
bristol
build
busy
calls
candidate
capital
Language
unset
8
×
Current search:
unset
×
" eli lilly "
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More